Saltar al contenido
Merck

SAE0217

Sigma-Aldrich

Enhanced Microbial Transglutaminase

new

Glycosylation tolerant, for site-specific antibody bioconjugation

Sinónimos:

Protein-Glutamine-γ-Glutamyltransferase, Protein-glutamine:amine γ-glutamyltransferase, eMTG

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

UNSPSC Code:
12352204

recombinant

expressed in E. coli

Quality Level

specific activity

≥30 units/mg protein

shipped in

dry ice

storage temp.

-10 to -25°C

General description

eMTG (Enhanced Microbial Transglutaminase) is an enzyme that catalyzes the formation of new isopeptide bonds between the primary amine of a drug linker and glutamine residues at position Q295 of IgG-type antibodies to produce site-specifically conjugated antibody-drug conjugates (ADCs).

Application

Site-specific conjugation is increasingly used in drug research, development, and manufacturing to produce ADCs and bioconjugates with defined drug-to-antibody ratios (DAR) since the resulting homogeneity improves safety and efficacy. Transglutaminase (TG)-mediated bioconjugation is a promising means of conjugating drug linkers specifically to the Q295 position of antibodies. However, its use traditionally requires antibody or glycan engineering since the adjacent glycosylation at N297 interferes with the TG reaction. If you are interested in trying eMTG to make therapeutic ADCs but do not currently have the conjugation setup/expertise, please consider ADC Express™ Service for pre-clinical lead candidate selection.

Features and Benefits

• Increased efficiency - with one-step bioconjugation for ADCs

• Glycosylation-tolerant - no need to remove glycosylation allowing for a preserved glycan on the antibody conjugate product

• Built for purpose - eMTG has been designed for producing ADCs and bioconjugates

• For higher-grade quality suitable for cGMP manufacturing of ADCs, please reach out using this form https://www.sigmaaldrich.com/US/en/services/contract-manufacturing/adc-bioconjugation/adc-bioconjugation-request-information with eMTG selected.

Unit Definition

One unit will catalyze the formation of 1.0 micromole of hydroxamate per minute from N Z GLN-GLY and hydroxylamine at pH 6.0 at 37°C.

pictograms

Health hazard

signalword

Danger

hcodes

Hazard Classifications

Resp. Sens. 1

Storage Class

11 - Combustible Solids

wgk_germany

WGK 1


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Stephan Dickgiesser et al.
Bioconjugate chemistry, 31(4), 1070-1076 (2020-03-07)
Site-specific bioconjugation technologies are frequently employed to generate homogeneous antibody-drug conjugates (ADCs) and are generally considered superior to stochastic approaches like lysine coupling. However, most of the technologies developed so far require undesired manipulation of the antibody sequence or its
Stephan Dickgiesser et al.
Methods in molecular biology (Clifton, N.J.), 2012, 135-149 (2019-06-05)
Antibody-drug conjugates (ADCs) are a relatively young class of cancer therapeutics that combine the superior selectivity of monoclonal antibodies (mAbs) with the high potency of cytotoxic agents. In the first generation of ADCs, the toxic payload is attached to the

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico